{
  "docId": "019de075-e109-770f-8f32-3054686041b6",
  "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Spyre Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 38,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/19",
  "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
  "deckJsonHref": "/decks/019de075-e109-770f-8f32-3054686041b6.json",
  "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.076,
        "w": 0.369,
        "x": 0.631,
        "y": 0.675
      },
      "kind": "callout",
      "text": "INTERIM PHASE 1 PK DATA EXPECTED YE2024",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d945baff-3e52-48a3-b7ef-6d974fba56ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.088,
        "w": 0.06,
        "x": 0.758,
        "y": 0.298
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b3785b7-d03a-4590-938f-db4f76ad906e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.084,
        "w": 0.045,
        "x": 0.478,
        "y": 0.302
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4dd349a7-8eb7-409f-a027-61ee6eed2241",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.088,
        "w": 0.06,
        "x": 0.198,
        "y": 0.298
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a120d4f-f357-46a8-b952-42cd03f4fcdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.201,
        "x": 0.657,
        "y": 0.468
      },
      "kind": "paragraph",
      "text": "DEVELOPING PATIENT SELECTION APPROACHES TO IDENTIFY RESPONDERS",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d99c213-4658-41f3-a9a4-ca15db7011ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.088,
        "w": 0.201,
        "x": 0.4,
        "y": 0.454
      },
      "kind": "paragraph",
      "text": "PK MODELLING SUPPORTS Q8-12W SC DOSING; UPSIDE POTENTIAL FOR GREATER INDUCTION EFFICACY",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4914702a-5176-49f2-a2bb-469102395f37",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.16,
        "x": 0.148,
        "y": 0.465
      },
      "kind": "paragraph",
      "text": "COMPARABLE IN VITRO PERFORMANCE TO VEDOLIZUMAB",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc3f7f0d-4e2c-42c8-8fe3-aefb0753baad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.093,
        "w": 0.288,
        "x": 0.026,
        "y": 0.043
      },
      "kind": "title",
      "text": "SPY001 summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e855d8ae-322e-431e-b3a1-6bc3bf03d7c8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "c3eb95f8-22ba-44db-9393-85d1d747138d",
      "evidence": "paragraph/paragraph: PK MODELLING SUPPORTS Q8-12W SC DOSING; UPSIDE POTENTIAL FOR GREATER INDUCTION EFFICACY",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}